Sergio Jobim Azevedo

Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma: 5-year analysis of KEYNOTE-426.

E. Plimack, B. Melichar, B. Rini, 2023, Journal of Clinical Oncology.